CytoSeek Join The Unit DX Labs

CytoSeek is the latest company to take up lab space at Unit DX as they continue to scale up their development of the next generation of cell therapies.

The pioneering cell membrane augmentation company, a spin-out of the University of Bristol, will now be based in Lab 04 to enable them to continue their growth.

Completing the transition from virtual member to taking a dedicated lab space, CytoSeek has now positioned itself within the Bristol-based science community of entrepreneurs and innovators spearheading a quiet revolution in the UK science industry.

Setting up lab space at the science incubator allows them to further their work developing an innovative new cell-augmentation technique, which it is hoped will revolutionise cell therapies. Access to state of the art facilities, lab space and instrumentation enables the team at CytoSeek to accelerate their proof-of-concept studies to demonstrate the enhancement of cell therapies for the treatment of solid tumours.

Dr Carolyn Porter, CEO, CytoSeek said:

“We are delighted to join the thriving community of innovative technology companies at Unit DX and look forward to an acceleration of activities towards our mission of improving the efficacy of cell therapies for the benefit of patients with difficult to treat forms of cancer. The Unit DX team and member companies have been incredibly supportive of our business, particularly through the Covid-19 induced lockdown period and we look forward to working more closely with the Unit DX community going forward.”

The move demonstrates that as the world adjusts to the challenges of Covid-19 ambitious science companies in Bristol are forging ahead with their growth plans. In November 2019 CytoSeek raised £1.1 million in funding to develop next-generation cell therapies.

Cytoseek are developing technology that builds on the research of Adam Perriman, a Professor of Bioengineering in the School of Cellular and Molecular Medicine, University of Bristol. Their mission is to unlock the potential of advanced cell therapies by enhancing their ability to effectively treat cancer patients with solid tumours.

Cytoseek have been associated with Unit DX since 2017 and have benefitted from incubation and support services as a virtual member.

Dr Ashley Brewer, Unit DX Centre Director, said:

“On behalf of the team at Unit DX I’d like to welcome Cytoseek into their new lab space. We’ve been watching with excitement as the business grows and their research builds momentum and attention. I’m delighted that they have taken up private lab space with us after being a virtual member since 2017. I look forward to working closely with them as I’m sure are the existing member companies here.”

Hear Dr Carolyn Porter, CEO of Cytoseek, speak at the upcoming South West Advanced Therapies (SWAT) Network Event on Wednesday 22/7/2020 @ 4pm

To view the full agenda for the event and to register to attend click here.

Read more about the exciting work of Cytoseek in The Science Behind the Technology.

By | 2020-07-22T12:40:54+01:00 July 22nd, 2020|News|